Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Chinese Patent Office
Colorcon
Farmers Insurance
McKesson
Queensland Health
Harvard Business School
McKinsey
Cantor Fitzgerald

Generated: December 14, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR REVATIO

« Back to Dashboard

Clinical Trials for Revatio

Trial ID Title Status Sponsor Phase Summary
NCT00359736 Sildenafil Study to Treat Idiopathic Pulmonary Fibrosis Completed VA Office of Research and Development Phase 2 Medicines that decrease blood pressure in the lungs may help idiopathic pulmonary fibrosis (IPF) patients function better. This study will test whether sildenafil improves the ability to exercise in patients with pulmonary fibrosis of unknown cause.
NCT00452218 Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH) Completed Bayer Phase 1 The purpose of this study is to assess the safety and tolerability of sorafenib in patients with PAH already on existing therapy with a prostacyclin [epoprostenol (Flolan)], treprostinil (Remodulin), or iloprost alone, or with or without sildenafil (Viagra/Revatio).
NCT00452218 Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH) Completed University of Chicago Phase 1 The purpose of this study is to assess the safety and tolerability of sorafenib in patients with PAH already on existing therapy with a prostacyclin [epoprostenol (Flolan)], treprostinil (Remodulin), or iloprost alone, or with or without sildenafil (Viagra/Revatio).
NCT00507819 Sildenafil After the Fontan Operation Completed The Mark H. and Blanche M. Harrington Foundation Phase 2 In this study, the investigators will evaluate the effect of sildenafil on exercise tolerance in patients with a single cardiac ventricle who have undergone the Fontan operation. The investigators will also evaluate echocardiographic measures of ventricular function and measure quality of life changes using two validated quality of life measures. The hypothesis is that sildenafil will result in increased exercise tolerance in patients who have had the Fontan operation as compared to placebo.
NCT00507819 Sildenafil After the Fontan Operation Completed Children's Hospital of Philadelphia Phase 2 In this study, the investigators will evaluate the effect of sildenafil on exercise tolerance in patients with a single cardiac ventricle who have undergone the Fontan operation. The investigators will also evaluate echocardiographic measures of ventricular function and measure quality of life changes using two validated quality of life measures. The hypothesis is that sildenafil will result in increased exercise tolerance in patients who have had the Fontan operation as compared to placebo.
NCT00586794 Therapy of Pulmonary Arterial Hypertension (PAH) - Treatment With Sildenafil in Eisenmenger Patients Terminated German Federal Ministry of Education and Research Phase 3 Eisenmenger's syndrome presents as a severe clinical picture of polymorbidity that constitutes a great burden at the individual as well as the familial and social level. The combination of critically increased pulmonary vascular resistance, progressive pressure load of the right ventricle and disturbance of pulmonary gas exchange result in long-term polymorbidity. The objective of this study is to provide evidence of improvement of patients exercise tolerance as well as general conditions by treatment with oral sildenafil as a specific pulmonary vasodilator.
NCT00586794 Therapy of Pulmonary Arterial Hypertension (PAH) - Treatment With Sildenafil in Eisenmenger Patients Terminated Competence Network for Congenital Heart Defects Phase 3 Eisenmenger's syndrome presents as a severe clinical picture of polymorbidity that constitutes a great burden at the individual as well as the familial and social level. The combination of critically increased pulmonary vascular resistance, progressive pressure load of the right ventricle and disturbance of pulmonary gas exchange result in long-term polymorbidity. The objective of this study is to provide evidence of improvement of patients exercise tolerance as well as general conditions by treatment with oral sildenafil as a specific pulmonary vasodilator.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Revatio

Condition Name

Condition Name for Revatio
Intervention Trials
Pulmonary Arterial Hypertension 7
Pulmonary Hypertension 6
Hypertension, Pulmonary 3
Cystic Fibrosis 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Revatio
Intervention Trials
Hypertension 20
Hypertension, Pulmonary 15
Familial Primary Pulmonary Hypertension 9
Fibrosis 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Revatio

Trials by Country

Trials by Country for Revatio
Location Trials
United States 80
Germany 14
Canada 9
Belgium 5
Spain 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Revatio
Location Trials
California 7
North Carolina 5
Arizona 4
Texas 4
Ohio 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Revatio

Clinical Trial Phase

Clinical Trial Phase for Revatio
Clinical Trial Phase Trials
Phase 4 7
Phase 3 7
Phase 2/Phase 3 2
[disabled in preview] 34
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Revatio
Clinical Trial Phase Trials
Completed 28
Not yet recruiting 6
Recruiting 4
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Revatio

Sponsor Name

Sponsor Name for Revatio
Sponsor Trials
Pfizer 15
National Heart, Lung, and Blood Institute (NHLBI) 5
Duke University 4
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Revatio
Sponsor Trials
Other 56
Industry 21
NIH 9
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Argus Health
McKesson
US Department of Justice
Cipla
Queensland Health
Colorcon
Cantor Fitzgerald
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.